The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) today expressed the research-based pharmaceutical industry’s support for calls to extend the deadline for Least-Developed Countries to comply with the provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
Mr. David Brennan, President of the IFPMA and CEO of AstraZeneca, said: “We recognize the significant development challenges experienced by Least-Developed Countries and believe that an extension would be useful to allow for effective TRIPS implementation. Such an extension should be used to align implementation across all areas of technology, to ensure a consistent approach. Our industry continues to believe that effective Intellectual Property Rights are a crucial component of long-term economic development within these countries, and international organizations and national bodies should continue to provide technical assistance, based on specific in-country needs.”
Geneva, 10 February 2011
